STOCK TITAN

Avalo Therapeutics (AVTX) 424B Filings

AVTX NASDAQ

Here are the 424B prospectus supplements from Avalo Therapeutics, Inc. (AVTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.

Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) may offer and sell common stock with an aggregate offering price of up to $200,000,000 from time to time through Jefferies under an at-the-market sales agreement; sales may also occur in negotiated transactions, including block trades. Jefferies is not required to sell a specific amount and may receive a commission of up to 3.0% of gross proceeds from shares it sells.

Avalo intends to use net proceeds, if any, primarily for ongoing clinical development of abdakibart and AVTX-010, working capital and other general corporate purposes. Common shares outstanding were 53,923,083 as of September 30, 2026. The offering illustration assumes a sale of 27,322,404 shares at $7.32 per share, the last reported sale price on November 2, 2026, and lists up to 81,245,487 shares outstanding immediately after the offering, assuming no options or warrants are exercised, preferred stock is converted, or restricted or performance stock units vest. Avalo also reports that Phase 2 LOTUS met its primary endpoint, citing a 42.5% combined absolute improvement in HiSCR75 response at Week 16 and a 25.6% placebo rate.

Rhea-AI Summary

Avalo Therapeutics, Inc. filed a resale prospectus covering up to 128,189 shares of common stock, $0.001 par value, held by former AlmataBio stockholders under a Milestone Buyout Amendment Agreement. All shares may be sold from time to time by the selling stockholders; Avalo is not selling shares and will not receive proceeds from these resales.

Avalo is a clinical-stage biotechnology company focused on therapies targeting the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases. Lead antibody abdakibart (AVTX-009) met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa and is planned for advancement into a registrational Phase 3 program. As of July 10, 2026, there were 52,902,989 shares of common stock outstanding; AVTX trades on Nasdaq Capital Market, last reported at $19.50 per share on July 27, 2026.

Rhea-AI Summary

Avalo Therapeutics is offering 19,730,000 shares of common stock and pre-funded warrants to purchase up to 1,400,000 additional shares. The offering price is $17.75 per share and each pre-funded warrant has an exercise price of $0.001 per share. The company estimates net proceeds of approximately $352.1 million, which it intends to use to advance the clinical development of abdakibart (AVTX-009) into a Phase 3 registrational program, for working capital and general corporate purposes. Avalo reported $82.0 million of cash, cash equivalents and short-term investments as of March 31, 2026. The pre-funded warrants are non‑expiring, subject to ownership limits (4.99% default; holder may elect 9.99%), and are not expected to be listed.

Rhea-AI Summary

Avalo Therapeutics is offering shares of its common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable for common stock, subject to 4.99% (or, at holder election, 9.99%) ownership limits. The company reported positive Phase 2 topline results for abdakibart in HS and lists common stock on Nasdaq under AVTX. The prospectus describes underwriting arrangements, an underwriter option to purchase additional shares, intended use of proceeds to advance abdakibart into Phase 3, and a preliminary cash position of approximately $82.0 million as of March 31, 2026.